Merck & Company Inc (MRK)vsProgyny Inc (PGNY)
MRK
Merck & Company Inc
$109.18
+2.74%
HEALTHCARE · Cap: $274.03B
PGNY
Progyny Inc
$18.58
+0.87%
HEALTHCARE · Cap: $1.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4945% more annual revenue ($65.01B vs $1.29B). MRK leads profitability with a 28.1% profit margin vs 4.5%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PGNY
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+69.5%
Fair Value
$70.58
Current Price
$18.58
$52.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Earnings expanding 20.6% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Moderate valuation
Smaller company, higher risk/reward
4.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PGNY
The strongest argument for PGNY centers on Altman Z-Score, Price/Book, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PGNY
The primary concerns for PGNY are P/E Ratio, Market Cap, Profit Margin. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
PGNY carries more volatility with a beta of 0.99 — expect wider price swings.
PGNY is growing revenue faster at 6.7% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 50/100), backed by strong 28.1% margins. PGNY offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Progyny Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?